Fulvestrant Injection
Product Images NDC 71731-6121

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 71731-6121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (M01 Fig 01)

Figure 1 (M01 Fig 01)
FDA Label Image

Figure 2 (M01 Fig 02)

Figure 2 (M01 Fig 02)
FDA Label Image

Figure 3 (M01 Fig 03)

Figure 3 (M01 Fig 03)
FDA Label Image

Figure 4 (M01 Fig 04)

Figure 4 (M01 Fig 04)
FDA Label Image

Figure 5 (M01 Fig 05)

Figure 5 (M01 Fig 05)
FDA Label Image

Figure 6 (M01 Fig 06)

Figure 6 (M01 Fig 06)
FDA Label Image

Figure 7 (M01 Fig 07)

Figure 7 (M01 Fig 07)
This is a table that shows the Progression Free Survival for two doses of Fulvestrant (250mg and 500mg) over the course of 45 months. The information shows the number of patients at risk for each time point.*
FDA Label Image

M01 Fig 08

M01 Fig 08
FDA Label Image

Figure 9 (M01 Fig 09)

Figure 9 (M01 Fig 09)
FDA Label Image

Figure 10 (M01 Fig 10)

Figure 10 (M01 Fig 10)
This appears to be a graph displaying the "Progression-Free Survival Probability" for two different treatments: "fulvestrant+palbociclib" and "fulvestrant+placebo". The X-axis shows the time in months and the Y-axis displays the survival probability in percentages. The number of patients at risk is indicated but it is not clear what the exact numbers represent without context.*
FDA Label Image

Figure 11 (M01 Fig 11)

Figure 11 (M01 Fig 11)
The text describes survival probability percentages for two drug combinations (fulvestrant+palbociclib and fulvestrant+placebo) for the different stages of time (in months). The description is accompanied by the number of patients at risk for each drug combination. Therefore, this text is useful for examining clinical trial results for these two drug combinations.*
FDA Label Image

Figure 12 (M01 Fig 12)

Figure 12 (M01 Fig 12)
FDA Label Image

M01 Fig 13

M01 Fig 13
FDA Label Image

M01 Fig 14

M01 Fig 14
FDA Label Image

M01 Fig 15

M01 Fig 15
FDA Label Image

M01 Fig 16

M01 Fig 16
This is a description of a medication called Fulvestrant Injection. It comes in a package that includes two single-dose pre-filled syringes with a 250mg dosage each. This medication is administered through an intramuscular injection. The text is partially garbled and has some errors, but the general information about the medication is discernible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.